■ Phosphodiesterase type 5 inhibitors and COVID-19: Are they useful in disease management?

Nicola Mondaini

World J Mens Health. 2020 Jul; 38(3): 254–255

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308240/

 

■ Is non-chlamydial non-gonococcal urethritis associated with significant clinical complication in men? A systematic review

Cassandra E.L. Fairhead, Alexander Hampson, Louis Dwyer-Hemmings, Nikhil Vasdev

Curr Urol. 2020 Mar; 14(1): 1–13

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206600/

 

■ Should all men with type 2 diabetes be routinely prescribed a phosphodiesterase type 5 inhibitor?

Geoffrey Hackett

World J Mens Health. 2020 Jul; 38(3): 271–284

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308237/

 

■ Metabolic syndrome and the composition of urinary calculi: is there any relation?

Pedro Valente, Hélder Castro, Inês Pereira et al

Cent European J Urol. 2019; 72(3): 276–279

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830491/

 

■ Testosterone and dehydroepiandrosterone treatment in ageing men: Are we all set?

Andreas Walther, Julian Seuffert

World J Mens Health. 2020 Apr; 38(2): 178–190

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076306/

 

■ Does urethral length affect continence outcomes follwing robot assisted laparoscopic radical prostatectomy (RALP)?

Diwei Lin, Michael O’Callaghan, Rowan David, et al

BMC Urol. 2020; 20: 8

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995073/

 

■ Post-radical prostactomy urinary incontinence: is there any discrepancy between medical reports and patients perceptions?

Rafael Castilho Borges, Marcos Tobias-Machado, Estefânia Nicoleti Gabriotti, et al

BMC Urol. 2019; 19: 32

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501406/

 

■ Is there a role for levo-thyroxine for the treatment of arterial erectile dysfunction? The clinical relevance of the mean platelet volume

Rossella Cannarella, Aldo E. Calogero, Antonio Aversa et al

J Clin Med. 2020 Mar; 9(3): 742

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141360/

 

■ Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?

Kerri Beckmann, Netty Kinsella, Henrik Olsson et al

BMC Urol. 2019; 19: 73

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683376/

 

■ Prostate cancer screening among elderly men in Brazil: should we diagnose or not?

Mori, Rafael Ribeiro et al.

Int. braz j urol., Feb 2020, vol.46, no.1, p.34-4

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000100034&lng=en&nrm=iso

 

■ Co-treatment of lower urinary tract symptoms and cardiovascular disease – where do we stand?

Karolina Semczuk-Kaczmarek, Anna E. Płatek, Filip M. Szymański

Cent European J Urol. 2020; 73(1): 42–4

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203768/

 

■ Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower urinary tract symptoms

Nassim Aourag, Johan F. Langenhuijsen, Frank d’Ancona, John Heesakkers

Cent European J Urol. 2019; 72(1): 39–4

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469014/

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: julho 2020